Global Breviscapine for Injection 麻豆原创 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR052512134

Publication Date:

May 20, 2025

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Breviscapine for Injection market size was valued at US$ 473 million in 2024 and is forecast to a readjusted size of USD 565 million by 2031 with a CAGR of 2.7% during review period.
Breviscapine for injection is a sterile injection made from the traditional Chinese medicine Breviscapine, which is extracted by modern technology to extract the active ingredients (mainly scutellarin), and has the effects of promoting blood circulation, removing blood stasis, unblocking meridians and relieving pain. Its main ingredient is scutellarin, which is clinically used to treat stroke sequelae, coronary heart disease, angina pectoris and other cardiovascular and cerebrovascular diseases.
This report is a detailed and comprehensive analysis for global Breviscapine for Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Breviscapine for Injection market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Breviscapine for Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Breviscapine for Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Breviscapine for Injection market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Breviscapine for Injection
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Breviscapine for Injection market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Kunming Longjin Pharmaceutical, China Shineway Pharmaceutical, YUNNAN BIOVALLEY PHARMACEUTICAL, Hunan Hengsheng Pharmaceutical, Tasly Pharmaceutical Group, KPC Pharmaceuticals, Sihuan Pharmaceutical, CSPC Pharmaceutical Group, Jilin Longtai Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Breviscapine for Injection market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Freeze-Dried Powder
Aqueous Solution
麻豆原创 segment by Application
Hospital
Clinic
Other
Major players covered
Kunming Longjin Pharmaceutical
China Shineway Pharmaceutical
YUNNAN BIOVALLEY PHARMACEUTICAL
Hunan Hengsheng Pharmaceutical
Tasly Pharmaceutical Group
KPC Pharmaceuticals
Sihuan Pharmaceutical
CSPC Pharmaceutical Group
Jilin Longtai Pharmaceutical
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Breviscapine for Injection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Breviscapine for Injection, with price, sales quantity, revenue, and global market share of Breviscapine for Injection from 2020 to 2025.
Chapter 3, the Breviscapine for Injection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Breviscapine for Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Breviscapine for Injection market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Breviscapine for Injection.
Chapter 14 and 15, to describe Breviscapine for Injection sales channel, distributors, customers, research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Breviscapine for Injection Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Freeze-Dried Powder
1.3.3 Aqueous Solution
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Breviscapine for Injection Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Breviscapine for Injection 麻豆原创 Size & Forecast
1.5.1 Global Breviscapine for Injection Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Breviscapine for Injection Sales Quantity (2020-2031)
1.5.3 Global Breviscapine for Injection Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Kunming Longjin Pharmaceutical
2.1.1 Kunming Longjin Pharmaceutical Details
2.1.2 Kunming Longjin Pharmaceutical Major Business
2.1.3 Kunming Longjin Pharmaceutical Breviscapine for Injection Product and Services
2.1.4 Kunming Longjin Pharmaceutical Breviscapine for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Kunming Longjin Pharmaceutical Recent Developments/Updates
2.2 China Shineway Pharmaceutical
2.2.1 China Shineway Pharmaceutical Details
2.2.2 China Shineway Pharmaceutical Major Business
2.2.3 China Shineway Pharmaceutical Breviscapine for Injection Product and Services
2.2.4 China Shineway Pharmaceutical Breviscapine for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 China Shineway Pharmaceutical Recent Developments/Updates
2.3 YUNNAN BIOVALLEY PHARMACEUTICAL
2.3.1 YUNNAN BIOVALLEY PHARMACEUTICAL Details
2.3.2 YUNNAN BIOVALLEY PHARMACEUTICAL Major Business
2.3.3 YUNNAN BIOVALLEY PHARMACEUTICAL Breviscapine for Injection Product and Services
2.3.4 YUNNAN BIOVALLEY PHARMACEUTICAL Breviscapine for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 YUNNAN BIOVALLEY PHARMACEUTICAL Recent Developments/Updates
2.4 Hunan Hengsheng Pharmaceutical
2.4.1 Hunan Hengsheng Pharmaceutical Details
2.4.2 Hunan Hengsheng Pharmaceutical Major Business
2.4.3 Hunan Hengsheng Pharmaceutical Breviscapine for Injection Product and Services
2.4.4 Hunan Hengsheng Pharmaceutical Breviscapine for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Hunan Hengsheng Pharmaceutical Recent Developments/Updates
2.5 Tasly Pharmaceutical Group
2.5.1 Tasly Pharmaceutical Group Details
2.5.2 Tasly Pharmaceutical Group Major Business
2.5.3 Tasly Pharmaceutical Group Breviscapine for Injection Product and Services
2.5.4 Tasly Pharmaceutical Group Breviscapine for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Tasly Pharmaceutical Group Recent Developments/Updates
2.6 KPC Pharmaceuticals
2.6.1 KPC Pharmaceuticals Details
2.6.2 KPC Pharmaceuticals Major Business
2.6.3 KPC Pharmaceuticals Breviscapine for Injection Product and Services
2.6.4 KPC Pharmaceuticals Breviscapine for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 KPC Pharmaceuticals Recent Developments/Updates
2.7 Sihuan Pharmaceutical
2.7.1 Sihuan Pharmaceutical Details
2.7.2 Sihuan Pharmaceutical Major Business
2.7.3 Sihuan Pharmaceutical Breviscapine for Injection Product and Services
2.7.4 Sihuan Pharmaceutical Breviscapine for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Sihuan Pharmaceutical Recent Developments/Updates
2.8 CSPC Pharmaceutical Group
2.8.1 CSPC Pharmaceutical Group Details
2.8.2 CSPC Pharmaceutical Group Major Business
2.8.3 CSPC Pharmaceutical Group Breviscapine for Injection Product and Services
2.8.4 CSPC Pharmaceutical Group Breviscapine for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 CSPC Pharmaceutical Group Recent Developments/Updates
2.9 Jilin Longtai Pharmaceutical
2.9.1 Jilin Longtai Pharmaceutical Details
2.9.2 Jilin Longtai Pharmaceutical Major Business
2.9.3 Jilin Longtai Pharmaceutical Breviscapine for Injection Product and Services
2.9.4 Jilin Longtai Pharmaceutical Breviscapine for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Jilin Longtai Pharmaceutical Recent Developments/Updates
3 Competitive Environment: Breviscapine for Injection by Manufacturer
3.1 Global Breviscapine for Injection Sales Quantity by Manufacturer (2020-2025)
3.2 Global Breviscapine for Injection Revenue by Manufacturer (2020-2025)
3.3 Global Breviscapine for Injection Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Breviscapine for Injection by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Breviscapine for Injection Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Breviscapine for Injection Manufacturer 麻豆原创 Share in 2024
3.5 Breviscapine for Injection 麻豆原创: Overall Company Footprint Analysis
3.5.1 Breviscapine for Injection 麻豆原创: Region Footprint
3.5.2 Breviscapine for Injection 麻豆原创: Company Product Type Footprint
3.5.3 Breviscapine for Injection 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Breviscapine for Injection 麻豆原创 Size by Region
4.1.1 Global Breviscapine for Injection Sales Quantity by Region (2020-2031)
4.1.2 Global Breviscapine for Injection Consumption Value by Region (2020-2031)
4.1.3 Global Breviscapine for Injection Average Price by Region (2020-2031)
4.2 North America Breviscapine for Injection Consumption Value (2020-2031)
4.3 Europe Breviscapine for Injection Consumption Value (2020-2031)
4.4 Asia-Pacific Breviscapine for Injection Consumption Value (2020-2031)
4.5 South America Breviscapine for Injection Consumption Value (2020-2031)
4.6 Middle East & Africa Breviscapine for Injection Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Breviscapine for Injection Sales Quantity by Type (2020-2031)
5.2 Global Breviscapine for Injection Consumption Value by Type (2020-2031)
5.3 Global Breviscapine for Injection Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Breviscapine for Injection Sales Quantity by Application (2020-2031)
6.2 Global Breviscapine for Injection Consumption Value by Application (2020-2031)
6.3 Global Breviscapine for Injection Average Price by Application (2020-2031)
7 North America
7.1 North America Breviscapine for Injection Sales Quantity by Type (2020-2031)
7.2 North America Breviscapine for Injection Sales Quantity by Application (2020-2031)
7.3 North America Breviscapine for Injection 麻豆原创 Size by Country
7.3.1 North America Breviscapine for Injection Sales Quantity by Country (2020-2031)
7.3.2 North America Breviscapine for Injection Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Breviscapine for Injection Sales Quantity by Type (2020-2031)
8.2 Europe Breviscapine for Injection Sales Quantity by Application (2020-2031)
8.3 Europe Breviscapine for Injection 麻豆原创 Size by Country
8.3.1 Europe Breviscapine for Injection Sales Quantity by Country (2020-2031)
8.3.2 Europe Breviscapine for Injection Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Breviscapine for Injection Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Breviscapine for Injection Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Breviscapine for Injection 麻豆原创 Size by Region
9.3.1 Asia-Pacific Breviscapine for Injection Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Breviscapine for Injection Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Breviscapine for Injection Sales Quantity by Type (2020-2031)
10.2 South America Breviscapine for Injection Sales Quantity by Application (2020-2031)
10.3 South America Breviscapine for Injection 麻豆原创 Size by Country
10.3.1 South America Breviscapine for Injection Sales Quantity by Country (2020-2031)
10.3.2 South America Breviscapine for Injection Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Breviscapine for Injection Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Breviscapine for Injection Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Breviscapine for Injection 麻豆原创 Size by Country
11.3.1 Middle East & Africa Breviscapine for Injection Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Breviscapine for Injection Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Breviscapine for Injection 麻豆原创 Drivers
12.2 Breviscapine for Injection 麻豆原创 Restraints
12.3 Breviscapine for Injection Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Breviscapine for Injection and Key Manufacturers
13.2 Manufacturing Costs Percentage of Breviscapine for Injection
13.3 Breviscapine for Injection Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Breviscapine for Injection Typical Distributors
14.3 Breviscapine for Injection Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Companies Mentioned:

Kunming Longjin Pharmaceutical
China Shineway Pharmaceutical
YUNNAN BIOVALLEY PHARMACEUTICAL
Hunan Hengsheng Pharmaceutical
Tasly Pharmaceutical Group
KPC Pharmaceuticals
Sihuan Pharmaceutical
CSPC Pharmaceutical Group
Jilin Longtai Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.